A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Despite approval for the treatment of various malignancies, clinical application of cytokines such as type I interferon (IFN) is severely impeded by their systemic toxicity. AcTakines (Activity-on-Target cytokines) are optimized immunocytokines that, when injected in mice, only reveal their activity...

Full description

Bibliographic Details
Main Authors: Anje Cauwels, Sandra Van Lint, Geneviève Garcin, Jennyfer Bultinck, Franciane Paul, Sarah Gerlo, José Van der Heyden, Yann Bordat, Dominiek Catteeuw, Lode De Cauwer, Elke Rogge, Annick Verhee, Gilles Uzé, Jan Tavernier
Format: Article
Language:English
Published: Taylor & Francis Group 2018-03-01
Series:OncoImmunology
Subjects:
actaferon
checkpoint inhibitors
dendritic cells
engineered immunocytokine
immunotherapy
targeting
toxicity
type i interferon
tumor microenvironment
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1398876

Internet

http://dx.doi.org/10.1080/2162402X.2017.1398876

Similar Items